We partner with inventors, research centers, and academic institutions leveraging our decades of experience and deep industry relationships to rapidly move novel therapeutic compounds into and through clinical development towards FDA approval.

Our Founders

Raised in excess of $2 billion
7 drugs approved by FDA
80 years combined experience financing biotech

Pipeline

Camelot’s pipeline includes therapeutics from inventors, research centers, academic institutions, and other companies around the globe. Our expertise is in oncology, neurologic disease, and orphan disease advancements.

Disclosures

Camelot BioCapital is not the issuing entity, a registered broker-dealer, or a crowdfunding portal, and is not acting in a regulated capacity in connection with any proposed issuance of investments referenced on this site. Camelot BioCapital does not provide investment advice, endorse, or offer analysis or recommendations regarding any investments mentioned on the site. Neither Camelot BioCapital nor any of our officers, directors, agents, or employees make any recommendations or endorsements regarding any investments on the site. Nothing on this site should be construed as an offer to sell, a distribution, or a solicitation of an offer to make an investment. No communication by Camelot BioCapital or any of its affiliates through this site or any other medium should be construed as a recommendation to purchase, sell, or hold any investment, or as investment, tax, financial, accounting, legal, regulatory, or compliance advice. Any investment information contained herein has been obtained from sources that Camelot BioCapital believes to be reliable, but we make no representations or warranties as to the accuracy of such information and accept no liability for any inaccuracies.